Maintenance Chemotherapy in Limited Small Cell Lung Cancer
Author Information
Author(s): M.J. Byrne, G. van Hazel, J. Trotter, F. Cameron, J. Shepherd, B. Cassidy, V. Gebski
Primary Institution: Sir Charles Gairdner Hospital
Hypothesis
Does maintenance chemotherapy improve survival in patients with limited small cell lung cancer after initial treatment?
Conclusion
Maintenance chemotherapy was associated with decreased survival compared to no maintenance therapy in patients with limited small cell lung cancer.
Supporting Evidence
- Patients receiving maintenance therapy had a median survival of 14.1 months compared to 19.2 months for those without maintenance.
- Among complete responders, median survival was 18.0 months for maintenance versus 26.8 months for no maintenance.
- Deaths were predominantly due to tumor progression, not toxicity from maintenance therapy.
Takeaway
This study found that giving more chemotherapy after initial treatment for lung cancer didn't help patients live longer and might even make things worse.
Methodology
Patients were randomly assigned to receive either maintenance chemotherapy or no maintenance after initial treatment, and their survival was tracked.
Potential Biases
There may be biases related to patient selection and the small number of participants.
Limitations
The study had a small sample size and may not be generalizable to all patients with small cell lung cancer.
Participant Demographics
Patients were 70 years of age or younger with histologically or cytologically proven small cell lung cancer.
Statistical Information
P-Value
0.05
Confidence Interval
10.1-17.0
Statistical Significance
p=0.05
Want to read the original?
Access the complete publication on the publisher's website